PubMed Central, : RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2014 October; 5(4): e0035. ISSN: 2076-9172Published online 2014 October 29. doi: 10.5041/RMMJ.10169.

Table 2.

The Various Clinical and Therapeutic Particularities of PMF According to JAK2 or CALR Molecular Subtypes.

		JAK2V617F-mutated ET	CALR-mutated ET
Age		Older	Younger
Blood counts	Hemoglobin	Higher	Lower
	Platelet	Lower	Higher
	White blood count	Higher	Lower
Overall survival			Longer, may be restricted only to patients with type 1 CALR mutations
Treatment implications		Stem cell transplant should be considered not only for DIPSS-plus high-risk myelofibrosis but also for any-risk disease with CALR(−)/ASXL1(+) mutational status

RMMJ Rambam Maimonides Medical Journal Rambam Health Care Campus 2014 October; 5(4): e0035. ISSN: 2076-9172

Published online 2014 October 29. doi: 10.5041/RMMJ.10169